Playtex S&E
This article was originally published in The Rose Sheet
Executive Summary
Third quarter sun care sales soared 100% to $6.8 mil. compared to "very small" sales gain during the prior year period, an 1Oct. 31 Playtex release states. Low, single digit sales growth is expected in 2002, with sun care "on the upper end" of that range due to launches of Banana Boat Vitaskin sun care line and indoor tanning products, CEO Michael Gallagher reports. New products are expected to debut later this year (2"The Rose Sheet" July 30, p. 3). Consolidated sales for the quarter were flat at $187.6 mil., while net earnings plummeted 47.3% to $2.4 mil. including extraordinary loss on early extinguishments of debt...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.